MCID: CHR001
MIFTS: 48

Churg-Strauss Syndrome

Categories: Blood diseases, Cardiovascular diseases, Immune diseases

Aliases & Classifications for Churg-Strauss Syndrome

MalaCards integrated aliases for Churg-Strauss Syndrome:

Name: Churg-Strauss Syndrome 12 75 55 44 15 17 72
Allergic Granulomatosis Angiitis 12
Allergic Granulomatous Angiitis 12
Churg-Strauss Vasculitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3049
MeSH 44 D015267
NCIt 50 C34481
SNOMED-CT 68 82275008
ICD10 33 M30.1
UMLS 72 C0008728

Summaries for Churg-Strauss Syndrome

Disease Ontology : 12 A vasculitits that is systemic vasculitis realized as blood vessel inflammation and has symptom asthma along with hay fever, rash and gastrointestinal bleeding.

MalaCards based summary : Churg-Strauss Syndrome, also known as allergic granulomatosis angiitis, is related to microscopic polyangiitis and hypereosinophilic syndrome, and has symptoms including asthma An important gene associated with Churg-Strauss Syndrome is MPO (Myeloperoxidase), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Prednisone and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and heart, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Eosinophilic granulomatosis with polyangiitis (EGPA), also known as allergic granulomatosis, is an... more...

Related Diseases for Churg-Strauss Syndrome

Diseases related to Churg-Strauss Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)
# Related Disease Score Top Affiliating Genes
1 microscopic polyangiitis 33.4 TNF MPO
2 hypereosinophilic syndrome 32.3 RNASE3 IL5 CCL17
3 anca-associated vasculitis 31.8 PRTN3 MPO
4 rapidly progressive glomerulonephritis 31.8 PRTN3 MPO
5 chronic eosinophilic pneumonia 31.7 RNASE3 IL5
6 maxillary sinusitis 31.7 RNASE3 MPO
7 granulomatous angiitis 31.7 THBD PRTN3 IL5
8 eosinophilic gastroenteritis 31.6 RNASE3 IL5
9 eosinophilic pneumonia 31.5 RNASE3 IL5 CCL17
10 allergic rhinitis 31.2 RNASE3 MPO IL5 IL10
11 eosinophilic gastritis 31.1 IL5 CCL26
12 endomyocardial fibrosis 31.1 TNF IL10
13 glomerulonephritis 31.1 PRTN3 MPO CD40LG
14 ige responsiveness, atopic 30.9 RNASE3 IL5 IL10
15 pulmonary eosinophilia 30.9 RNASE3 IL5 CCL17
16 hypersensitivity vasculitis 30.9 PRTN3 MPO
17 scleritis 30.8 TNF IL5
18 cellulitis 30.6 TNF RNASE3 IL5
19 vasculitis 30.5 TNF THBD PRTN3 MPO CD40LG
20 allergic bronchopulmonary aspergillosis 30.5 IL5 CCL17
21 peritonitis 30.5 TNF MPO IL10
22 otitis media 30.5 TNF RNASE3 IL10
23 colitis 30.4 TNF MPO IL10
24 multifocal choroiditis 30.3 TNF IL10
25 choroiditis 30.3 TNF IL10
26 bronchitis 30.3 TNF RNASE3 MPO IL5
27 erythema multiforme 30.3 TNF CCL17
28 proctitis 30.2 TNF RNASE3 MPO
29 henoch-schoenlein purpura 30.2 RNASE3 MPO
30 gastroenteritis 30.2 TNF RNASE3 IL5 IL10
31 allergic asthma 30.2 RNASE3 IL5 IL10 CCL17
32 pulmonary disease, chronic obstructive 30.2 TNF RNASE3 MPO
33 appendicitis 30.1 TNF MPO IL10
34 allergic hypersensitivity disease 30.1 RNASE3 IL5 IL10 CCL17
35 ulcerative colitis 30.0 TNF PRTN3 MPO IL10
36 intestinal disease 29.9 TNF MPO IL10
37 autoimmune disease 29.9 TNF IL10 CD40LG
38 inflammatory bowel disease 29.8 TNF MPO IL10
39 aspergillosis 29.8 TNF IL5 IL10 CCL17
40 bronchiolitis 29.5 TNF RNASE3 IL5 IL10
41 lung disease 29.2 TNF RNASE3 PRTN3 MPO IL5 IL10
42 demyelinating disease 29.2 TNF IL10 CD40LG
43 connective tissue disease 29.2 TNF IL10 CD40LG
44 proteasome-associated autoinflammatory syndrome 1 29.0 TNF RNASE3 MPO IL5 IL10
45 pneumonia 28.9 TNF MPO IL5 IL10 CD40LG
46 myocardial infarction 28.5 TNF THBD MPO IL10 CD40LG
47 schistosomiasis 28.5 TNF RNASE3 IL5 IL10 CD40LG
48 asthma 27.6 TNF RNASE3 MPO IL5 IL10 CD40LG
49 eosinophilic granulomatosis with polyangiitis 12.7
50 allergic angiitis 12.2

Graphical network of the top 20 diseases related to Churg-Strauss Syndrome:



Diseases related to Churg-Strauss Syndrome

Symptoms & Phenotypes for Churg-Strauss Syndrome

Symptoms:

12
  • asthma

MGI Mouse Phenotypes related to Churg-Strauss Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 CCL17 CD40LG IL10 IL5 MPO PRTN3
2 immune system MP:0005387 9.23 CCL17 CD40LG IL10 IL5 MPO PRTN3

Drugs & Therapeutics for Churg-Strauss Syndrome

Drugs for Churg-Strauss Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
3
leucovorin Approved Phase 4 58-05-9 143 6006
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Azathioprine Approved Phase 4 446-86-6 2265
10
rituximab Approved Phase 4 174722-31-7 10201696
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
13 Hormone Antagonists Phase 4
14 Anti-Inflammatory Agents Phase 4
15 Hormones Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
18 Gastrointestinal Agents Phase 4
19 Dermatologic Agents Phase 4
20 Folic Acid Antagonists Phase 4
21 Vitamin B9 Phase 4
22 Nucleic Acid Synthesis Inhibitors Phase 4
23 Vitamin B Complex Phase 4
24 Folate Phase 4
25 Antiemetics Phase 4
26 Neuroprotective Agents Phase 4
27 Methylprednisolone Acetate Phase 4
28 Prednisolone acetate Phase 4
29 Autonomic Agents Phase 4
30 Anti-Infective Agents Phase 4
31 Anti-Bacterial Agents Phase 4
32 Antitubercular Agents Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Antimetabolites Phase 4
35 Antimetabolites, Antineoplastic Phase 4
36 glucocorticoids Phase 4
37 Antibodies Phase 3
38 Immunoglobulins Phase 3
39 Immunoglobulin G Phase 3
40 Rho(D) Immune Globulin Phase 3
41 gamma-Globulins Phase 3
42 Immunoglobulins, Intravenous Phase 3
43 Benralizumab Approved, Investigational Phase 2 1044511-01-4
44
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
45
Ethanol Approved Phase 2 64-17-5 702
46 Reslizumab Approved, Investigational Phase 2
47
Abatacept Approved Phase 2 332348-12-6 10237
48 interferons Phase 1, Phase 2
49 Peripheral Nervous System Agents Phase 2
50 Narcotics Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients. Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
2 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
3 MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
4 A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy Completed NCT02020889 Phase 3 Placebo
5 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
6 Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
7 Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy) Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
8 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
9 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
10 The Efficacy and Safety of Benralizumab In the Treatment of Eosinophilic Grandulomatosis With Polyangiitis (EGPA) Study: BITE Unknown status NCT03010436 Phase 2 Benralizumab
11 A Phase II, Single Center Open Label, Prospective Trial to Evaluate the Efficacy and Safety of Mepolizumab for Patients With Refractory or Relapsing Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
12 Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
13 A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
14 An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
15 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
16 Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study Recruiting NCT02947945 Phase 2 Reslizumab
17 A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement Terminated NCT00424749 Phase 2 Rituximab;Prednisone
18 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
19 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
20 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
21 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
22 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
23 Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies Completed NCT00307593 Infliximab;Rituximab
24 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
25 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
26 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
27 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
28 The Serum Eosinophil Cationic Protein Levels in Behçet's Disease and Its Relation to the Clinical Activity Completed NCT01584778
29 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
30 Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Recruiting NCT00315380
31 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
32 Eosinophilic Granulomatosis With Polyangiitis Cohort Recruiting NCT03036670
33 VCRC Tissue Biorepository Collection Protocol Recruiting NCT02967068
34 The Vasculitis Pregnancy Registry (V-PREG) Recruiting NCT02593565
35 Clinical and Echocardiographic Evaluation of Patients With Granulomatosis With Polyangiitis Recruiting NCT03782870
36 VCRC Genetic Repository One-Time DNA Protocol Recruiting NCT01241305
37 Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes Recruiting NCT02006134
38 NUCALA ® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term) Active, not recruiting NCT03557060 Nucala
39 VCRC Validation of Patient-Reported Diagnostic Data Enrolling by invitation NCT02190942
40 A Pilot Study of Immuno-ablation With Chemoimmunoradiation Followed by Autologous Hematopoietic Progenitor Cell (HPC) Transplant for Adult Subjects With Churg-Strauss Syndrome Terminated NCT02728271 Early Phase 1
41 Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) Terminated NCT01934504

Search NIH Clinical Center for Churg-Strauss Syndrome

Cochrane evidence based reviews: churg-strauss syndrome

Genetic Tests for Churg-Strauss Syndrome

Anatomical Context for Churg-Strauss Syndrome

MalaCards organs/tissues related to Churg-Strauss Syndrome:

41
Lung, Neutrophil, Heart, Testes, T Cells, Colon, Skin

Publications for Churg-Strauss Syndrome

Articles related to Churg-Strauss Syndrome:

(show top 50) (show all 1986)
# Title Authors PMID Year
1
IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. 9 38
20513522 2010
2
A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. 9 38
19210866 2008
3
Pathways to ANCA production: from differentiation of dendritic cells by proteinase 3 to B lymphocyte maturation in Wegener's granuloma. 9 38
18181035 2008
4
Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). 9 38
17614969 2007
5
Meta-analysis of myeloperoxidase G-463/A polymorphism in anti-neutrophil cytoplasmic autoantibody-positive vasculitis. 9 38
17521322 2007
6
[Classification of systemic vasculatides]. 9 38
17408915 2007
7
Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. 9 38
17143091 2007
8
TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. 9 38
17699331 2006
9
Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. 9 38
12687504 2003
10
Benefit-risk assessment of antileukotrienes in the management of asthma. 9 38
12735786 2003
11
Autoantibodies in vasculitis. 9 38
12723981 2003
12
[Microscopic polyangiitis]. 9 38
10896971 2000
13
Distinct differences in autoantigen specificity of anti-neutrophil cytoplasm antibodies in systemic vasculitides and other inflammatory diseases. 9 38
11370121 1999
14
[Leprous neuropathy--observation from the standpoint vasculitis]. 9 38
10481446 1999
15
Pulmonary eosinophilia associated with montelukast. 9 38
10335014 1999
16
What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications. 9 38
10456261 1999
17
[Clinical study on five myeloperoxidase specific anti-neutrophil cytoplasmic antibody (MPO-ANCA) positive Churg-Strauss syndrome cases]. 9 38
9852746 1998
18
Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. 9 38
9506572 1998
19
[Eosinophil cationic protein in a 39-year-old patient with Churg-Strauss syndrome]. 9 38
9465849 1998
20
Systemic necrotizing vasculitis. 9 38
9220078 1997
21
[A case of Churg-Strauss syndrome in which MPO-ANCA (antibodies to myeloperoxidase) appeared to reflect the disease activity]. 9 38
7609341 1995
22
[Autoantibodies associated with vasculitis]. 9 38
7933581 1994
23
Correlation of antineutrophil cytoplasmic antibodies with the extrarenal histopathology of Wegener's (pathergic) granulomatosis and related forms of vasculitis. 9 38
8381764 1993
24
Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. 9 38
1466365 1992
25
[Antineutrophil cytoplasmic antibodies--ANCA]. 9 38
1464072 1992
26
Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. 9 38
1677531 1991
27
Pruritic skin involvement of necrotizing sarcoid granulomatosis: a case report. 38
31407372 2019
28
Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients. 38
31347324 2019
29
Cutaneous Vasculitis as Early Presentation of Eosinophilic Granulomatosis with Polyangiitis without Systemic Symptoms. 38
31360325 2019
30
Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis
. 38
31347497 2019
31
Update on eosinophilic granulomatosis with polyangiitis. 38
31266709 2019
32
Eosinophilic granulomatosis with polyangiitis in a Nigerian woman. 38
31217209 2019
33
Causes of eosinophilic ascites - A systematic review. 38
30864403 2019
34
[Current treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)]. 38
30627842 2019
35
Targeted immunotherapy strategies in ANCA-associated vasculitis. 38
30201478 2019
36
[Unexpected death due to eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)]. 38
30720008 2019
37
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Causes Aortic Valve Degeneration and Severe Aortic Regurgitation. 38
30930460 2019
38
Eosinophilic granulomatosis with polyangiitis in a continuous flow left ventricular assist device patient: a case report and review of literature. 38
30684748 2019
39
Ultrasound diagnosis of typhlitis. 38
30367357 2019
40
Massive Myocardial Necrosis due to Churg-Strauss Syndrome. 38
29884587 2019
41
Immunoglobulin G4-Related Disease Presenting with Clinical Similarity to Churg-Strauss Syndrome. 38
30772966 2019
42
Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature. 38
30134390 2019
43
Necrotizing Sarcoid Granulomatosis with Pneumothorax. 38
31275399 2019
44
Eosinophilic Granulomatosis with Polyangiitis Manifesting as Recurrent Nasal Polyps and Hemorrhagic Necrotic Bullae: A Rare Disease Successfully Treated with Azathioprine. 38
31043937 2019
45
Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature. 38
30179138 2019
46
Rare Manifestations of Churg-Strauss Syndrome with Mediastinal and Hilar Lymphadenopathies: Report of an Autopsy Case. 38
29249116 2019
47
Churg-strauss syndrome: clinical case and its feautures. 38
31055564 2019
48
Differential Diagnosis of Churg-Strauss Syndrome with Tingling Sensation and Weakness of the Lower Extremities. 38
30719419 2018
49
[Vasculitides and eosinophilic pulmonary diseases]. 38
30367242 2018
50
Histopathological Findings and Increased D-Dimer Are Predictive Factors of Systemic Thromboses in Eosinophilic Granulomatosis With Polyangiitis. 38
29979194 2018

Variations for Churg-Strauss Syndrome

Expression for Churg-Strauss Syndrome

Search GEO for disease gene expression data for Churg-Strauss Syndrome.

Pathways for Churg-Strauss Syndrome

Pathways related to Churg-Strauss Syndrome according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 TNF IL5 IL10 CD40LG CCL26 CCL17
2
Show member pathways
13.02 TNF IL5 IL10 CD40LG CCL26 CCL17
3
Show member pathways
12.63 TNF RNASE3 IL5 IL10 CD40LG
4 12.36 TNF MPO IL10 CD40LG
5
Show member pathways
12.3 TNF IL5 IL10 CD40LG
6
Show member pathways
12.13 TNF IL5 CCL17
7
Show member pathways
12.05 TNF IL10 CD40LG
8
Show member pathways
12 TNF IL10 CCL17
9
Show member pathways
11.88 IL5 IL10 CCL26 CCL17
10 11.69 TNF MPO IL5 IL10
11 11.62 TNF IL5 IL10
12
Show member pathways
11.58 TNF IL5 CD40LG
13 11.56 TNF THBD IL10
14 11.31 TNF IL10 CCL26 CCL17
15 11.3 TNF IL10 CD40LG
16 11.24 IL5 IL10 CCL17
17 11.13 IL5 CD40LG
18 11.11 TNF IL5
19 11.01 IL5 IL10
20 11.01 TNF IL5 IL10
21 10.82 IL5 IL10 CD40LG CCL26 CCL17
22 10.78 TNF MPO
23 10.66 TNF IL5 IL10 CD40LG CCL26 CCL17
24 10.64 TNF IL5 IL10 CD40LG CCL26 CCL17

GO Terms for Churg-Strauss Syndrome

Cellular components related to Churg-Strauss Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF RNASE3 PRTN3 MPO IL5 IL10
2 cell surface GO:0009986 9.56 TNF THBD GHSR CD40LG
3 azurophil granule lumen GO:0035578 9.33 RNASE3 PRTN3 MPO
4 extracellular space GO:0005615 9.32 TNF THBD RNASE3 PRTN3 MPO IL5

Biological processes related to Churg-Strauss Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.76 TNF PRTN3 IL5 IL10
2 response to lipopolysaccharide GO:0032496 9.73 THBD MPO IL10
3 cellular response to lipopolysaccharide GO:0071222 9.72 TNF IL10 GHSR
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.69 TNF IL5 IL10
5 defense response to bacterium GO:0042742 9.67 TNF RNASE3 MPO IL10
6 B cell proliferation GO:0042100 9.61 IL10 CD40LG
7 negative regulation of interleukin-6 production GO:0032715 9.6 TNF IL10
8 regulation of synapse organization GO:0050807 9.59 TNF IL10
9 positive regulation of sprouting angiogenesis GO:1903672 9.58 IL10 GHSR
10 positive regulation of cytokine secretion GO:0050715 9.58 TNF IL10
11 negative regulation of myoblast differentiation GO:0045662 9.57 TNF CCL17
12 response to food GO:0032094 9.54 MPO GHSR
13 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.52 TNF IL10
14 positive regulation of podosome assembly GO:0071803 9.49 TNF IL5
15 endothelial cell apoptotic process GO:0072577 9.48 TNF IL10
16 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.43 IL10 GHSR
17 immune response GO:0006955 9.43 TNF IL5 IL10 CD40LG CCL26 CCL17
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.4 TNF IL10
19 negative regulation of growth of symbiont in host GO:0044130 9.33 TNF MPO IL10
20 regulation of immunoglobulin secretion GO:0051023 9.32 TNF CD40LG
21 receptor biosynthetic process GO:0032800 9.26 TNF IL10
22 inflammatory response GO:0006954 9.1 TNF IL5 IL10 CD40LG CCL26 CCL17

Molecular functions related to Churg-Strauss Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.16 TNF CD40LG
2 cytokine activity GO:0005125 9.1 TNF IL5 IL10 CD40LG CCL26 CCL17
3 CCR chemokine receptor binding GO:0048020 8.96 CCL26 CCL17

Sources for Churg-Strauss Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....